The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Yue Pan(Central South University), Fang Wu(Central South University), Yurong Peng(Central South University), Yue Zeng(The University of Texas MD Anderson Cancer Center), Yuxuan Liu(Central South University), Chunhong Hu(Central South University), Chao Deng(Central South University), Xiaohan Liu(Central South University), Jian Zou(Central South University), Yucheng Fu(Ruijin Hospital), Zhenhua Qiu(Central South University)
Cited by 57
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
|Clinical Epigenetics|2021|253
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
|Nature Medicine|2024|116
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
|Frontiers in Oncology|2021|111
Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients
|Diabetes Research and Clinical Practice|2014|92